Bermekimab

{
  "id": "MLC-T-ONC-011958",
  "term": "Bermekimab",
  "field": "Oncology and biomedicine",
  "definition": "A human immunoglobulin (Ig) G1 monoclonal antibody directed against interleukin-1 alpha (IL-1a) and derived from human B lymphocytes that were obtained from a natural human immune response against IL-1a, with potential antineoplastic, anti-inflammatory, anti-cachectic and anti-angiogenic activities. Upon administration, bermekimab targets, binds to and neutralizes IL-1a thereby preventing IL-1a activity. This prevents IL-1a-mediated inflammation, tumorigenesis and angiogenesis. In addition, bermekimab may abrogate IL-1a-mediated cachexia and stimulate metabolic activity in the central nervous system (CNS). IL-1a, an inflammatory mediator expressed on monocytes, platelets and overexpressed by certain tumors, plays a key role in the promotion of tumor cell growth, metastasis and invasion.",
  "synonyms": [
    "anti-IL-1 alpha monoclonal antibody MABp1"
  ],
  "references": [
    "National Cancer Institute Thesaurus"
  ],
  "url": "https://mlchart.com/terminology/oncology/bermekimab/"
}